Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients:: Not simply overestimation

被引:17
作者
Cattaneo, D
Zenoni, S
Murgia, B
Merlini, S
Baldelli, S
Perico, N
Gotti, E
Ottomano, C
Crippa, A
Remuzzi, G
机构
[1] Mario Negri Inst Pharmacol Res, Osped Riuniti Bergamo, Dept Med & Transplantat, I-24125 Bergamo, Italy
[2] Osped Riuniti Bergamo, Lab Clin Anal, Bergamo, Italy
关键词
cyclosporine; immunoassays; HPLC; methods comparison;
D O I
10.1016/j.cccn.2004.12.018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Immunoassays used for the measurement of cyclosporine (CsA) usually show cross-reactivity for CsA metabolites, usually resulting in unacceptable bias. Methods: To assess the performance of different immunoassays, CsA concentrations were analyzed in 132 samples using ACMIA, EMIT-VIVA, CEDIA-PLUS, and HPLC. Samples were collected from kidney transplant patients monitored with the traditional blood CsA trough level (C-0, n=73) and the new sampling at 2-h post CsA dosing (C-2, n=59). Results: Overall, the correlations between HPLC and other methods were good (r values ranging from 0.85 to 0.97). The use of C-2 concentrations to monitor CsA exposure were associated with an overall better performance of all the immunoassays as compared with C-0 values. However, none of the immunoassays agreed with the guidelines. proposed in the Lake Louis Consensus Conference. Of note, the CEDIA-PLUS was the only that provided a linear relationship with HPLC for both sampling times. A false positive case associated with ACMIA was also documented in blood samples from a patient withdrawn from CsA for I month. Conclusion: These data suggest that the performance of some of the most used immunoassays is not satisfactory, eventually leading to incorrect therapeutic decision guided by erroneous CsA monitoring. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:153 / 164
页数:12
相关论文
共 30 条
[11]  
Gaspari F, 1998, CLIN TRANSPLANT, V12, P379
[12]   Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods [J].
Hamwi, A ;
Salomon, A ;
Steinbrugger, R ;
Fritzer-Szekeres, M ;
Jäger, W ;
Szekeres, T .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) :536-543
[13]  
Holt David W., 1997, Drug Metabolism and Drug Interactions, V14, P5
[14]   Quality assessment issues of new immunosuppressive drugs and experimental experience [J].
Holt, DW ;
Jones, K ;
Lee, T ;
Stadler, P ;
Johnston, A .
THERAPEUTIC DRUG MONITORING, 1996, 18 (04) :362-367
[15]   Monitoring cyclosporin in blood:: Between-assay differences at trough and 2 hours post-dose (C2) [J].
Johnston, A ;
Chusney, G ;
Schütz, E ;
Oellerich, M ;
Lee, TD ;
Holt, DW .
THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :167-173
[16]  
Johnston A, 2001, BRIT J CLIN PHARMACO, V52, p61S
[17]  
KAHAN BD, 1990, CLIN CHEM, V36, P1510
[18]   ROUTINE MONITORING OF CYCLOSPORINE IN WHOLE-BLOOD AND IN KIDNEY TISSUE USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
KAHN, GC ;
SHAW, LM ;
KANE, MD .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1986, 10 (01) :28-34
[19]   LAKE-LOUISE-CONSENSUS-CONFERENCE ON CYCLOSPORINE ONITORING IN ORGAN-TRANSPLANTATION - REPORT OF THE CONSENSUS PANEL [J].
OELLERICH, M ;
ARMSTRONG, VW ;
KAHAN, B ;
SHAW, L ;
HOLT, DW ;
YATSCOFF, R ;
LINDHOLM, A ;
HALLORAN, P ;
GALLICANO, K ;
WONIGEIT, K ;
SCHUTZ, E ;
SCHRAN, H ;
ANNESLEY, T .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :642-654
[20]  
PASSING H, 1981, J CLIN CHEM CLIN BIO, V19, P121